{
    "nct_id": "NCT03358472",
    "official_title": "A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)",
    "inclusion_criteria": "* Measurable disease based on RECIST v1.1.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate organ function per protocol-defined criteria.\n* Documentation of results from testing of human papilloma virus (HPV) status for oropharyngeal cancer.\n* Baseline archival tumor specimen available or willing to undergo a prestudy treatment tumor core or excisional biopsy of a tumor lesion not previously irradiated, to obtain the specimen.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Carcinoma of the nasopharynx, salivary gland, unknown primary origin, or nonsquamous histologies as primary tumors.\n* Disease progression within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC.\n* Use of protocol-defined prior/concomitant therapy.\n* Known additional malignancy that is progressing or has required active treatment within the past 3 years.\n* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.\n* Active autoimmune disease that has required systemic treatment in past 2 years.\n* Known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by local health authority.\n* Known history of or is positive for active hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (defined as HCV RNA [qualitative] is detected).",
    "miscellaneous_criteria": ""
}